Review Article

NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?

Gerardo G. Mackenzie, 1 Shaheen Rasheed, 2 William Wertheim, 3 and Basil Rigas 1, 2

1 Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794-5200, USA
2 Division of Gastroenterology, Department of Medicine, Stony Brook University, Stony Brook, NY 11794-5200, USA
3 Division of General Medicine, Department of Medicine, Stony Brook University, Stony Brook, NY 11794-5200, USA

Correspondence should be addressed to Basil Rigas, basil.rigas@stonybrook.edu

Received 2 March 2008; Revised 25 April 2008; Accepted 6 May 2008

Recommended by Dipak Panigrahy

The chemopreventive NO-donating NSAIDs (NO-NSAIDs; NSAIDs with an NO-releasing moiety) modulate PPARδ and offer the opportunity to revisit the controversial role of PPARδ in carcinogenesis (several papers report that PPARδ either promotes or inhibits cancer). This review summarizes the pharmacology of NO-NSAIDs, PPARδ cancer biology, and the relationship between the two. In particular, a study of the chemopreventive effect of two isomers of NO-aspirin on intestinal neoplasia in Min mice showed that, compared to wild-type controls, PPARδ is overexpressed in the intestinal mucosa of Min mice; PPARδ responds to m- and p-NO-ASA proportionally to their antitumor effect (p- > m-). This effect is accompanied by the induction of epithelial cell death, which correlates with the antineoplastic effect of NO-aspirin; and NO-aspirin’s effect on PPARδ is specific (no changes in PPARα or PPARγ). Although these data support the notion that PPARδ promotes intestinal carcinogenesis and its inhibition could be therapeutically useful, more work is needed before a firm conclusion is reached.

Copyright © 2008 Gerardo G. Mackenzie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Cancer represents a major health challenge of our time. In the last decade, biomedical science has pursued with unusual vigor the molecular understanding of cancer. Cell signaling cascades have, in particular, been examined or even recognized in the context of cancer research. The implicit assumption (as well as the expectation) has been that understanding the mechanisms of carcinogenesis will facilitate the development of rational, mechanism-driven interventions for either the treatment or even better the prevention of cancer. The ultimate “deliverable” of such systematic efforts will be successful cancer therapeutic or preventive agents.

As is, however, sometimes the case in science, mechanistic progress can also be made while trying to understand the mode of action of agents already developed. Such appears to be the case with the opportunity that presented itself while we were exploring the mode of action of a novel chemopreventive agent, nitric oxide-donating aspirin (NO-ASA), and its relationship to peroxisome proliferator-activated receptor δ (PPARδ). Here, we discuss our findings, and to provide an appropriate perspective, we summarize relevant aspects of the pharmacology of nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs), PPARδ cancer biology, and the relationship between the two.

2. NO-NSAIDs AND CANCER

NO-ASA, initially intended for rheumatologic and cardiovascular applications [1, 2], is a member of a large family of pharmacologically active compounds known as NO-donating NSAIDs (NO-NSAIDs). NO-NSAIDs consist of a conventional NSAID to which the NO-releasing moiety-ONO2 has been attached via a chemical linker [3, Figure 1]. In the case of NO-ASA, the spacer can vary in its chemical structure, generating a great number of derivatives. There are three positional isomers of the NO-ASA molecule (ortho, meta, and para), generated by varying the position of the –CH2ONO2 group with respect to the ester bond linking the two benzenes [4]. NO-ASA is the best studied NO-NSAID to date.
The impetus for the development of NO-NSAIDs for cancer prevention has been provided by extensive epidemiological data and interventional studies which over fifteen years have established conclusively conventional NSAIDs as chemopreventive agents against colon and other cancers [5, 6]. The limited efficacy (less than 50%) and side effects that accompany NSAIDs have prompted the search for better performing agents. NO-NSAIDs, especially NO-ASA, promise to be such an alternative, and their anticancer properties are now under intense study by our group and others. Even though significant progress has been made, the mechanism by which NO-ASA exerts its chemopreventive effect against colon cancer is still not completely understood [2]. Our data indicate that NO-ASA could exert its colon chemopreventive effect, at least in part, by modulating PPARδ function [7].

Extensive preclinical results have established that NO-ASA, which is now FDA approved for clinical trials, displays properties consistent with a chemopreventive effect [8]. These findings can be grouped into those documenting a favorable in vitro cytokinetic effect and those demonstrating chemopreventive efficacy in animal models of cancer. Compared to their corresponding parent compounds, several NO-NSAIDs (including NO-ASA, NO-sulindac and NO-ibuprofen, NO-salicylic acid, NO-indomethacin, and NO-flurbiprofen) have greater potency in inhibiting the growth of cancer cell lines, for example, colon, prostate, lung, pancreas, tonsil, breast cancer, and leukemia [9–12]. For example, in the case of colon cancer cell lines, the IC_{50} values of NO-NSAIDs were enhanced between 1.7- and 1083-fold. The growth-inhibitory effect of NO-NSAIDs is due to a profound cytokinetic effect, consisting of reduced cell proliferation, enhanced cell death, and inhibition of cell-cycle-phase transitions. Beyond classical apoptosis, NO-ASA induced another form of cell death, termed as atypical cell death [4]. Likely, a form of cell necrosis, atypical cell death, was initially described in vitro, but may actually occur in vivo [7].

The in vivo studies used orthotopic animal models of cancer as well as xenotransplants of human cancer cell lines in appropriate murine hosts. For colon cancer, the results from the various models are congruent and demonstrate a clear-cut chemopreventive effect. In Min mice, 3 weeks of treatment with NO-ASA decreased the number of tumors by 55% [13]. In F344 rats treated with the carcinogen azoxymethane, NO-indomethacin and meta NO-ASA significantly suppressed both tumor incidence and multiplicity (NO-indomethacin was more effective than NO-ASA). Of the two NO-ASA isomers, the para was more efficacious than the meta in Min mice [4]. When combined with 5-fluorouracil or oxaliplatin, para NO-ASA showed additive effects [14]. Sequential NO-ASA and oxaliplatin treatment reduced tumor growth more effectively than single-drug treatments, perhaps by sensitizing colon cancer cells to the effect of antitumor drugs. Studies using a hamster model of pancreatic cancer generated impressive results [15]. Compared with the control group, NO-ASA reduced the incidence and multiplicity of pancreatic cancer by 88.9% and 94%, respectively, whereas conventional ASA had no significant effect.

An exciting aspect of NO-ASA is its extraordinarily enhanced potency. We and others have attempted to understand this through studies assessing their effects on potentially informative pathways (summarized in [8]). It appears that NO-ASA has a pleiotropic effect involving several pathways, as depicted in Figure 1. PPARδ is a significant

![Figure 1: Effect of NO-ASA on PPARδ and other signaling pathways. NO-ASA consists of a traditional ASA molecule (shaded), the spacer, and –ONO2, which releases NO, with the molecule being considered responsible for much of its pharmacological properties. There are three positional isomers of NO-ASA (ortho, meta, and para), depending on the position of –ONO2 in the benzene ring with respect to the ester bond linking the ASA and spacer moieties. NO-ASA affects several cell signaling pathways, all relevant to carcinogenesis. The modulation of these often cross-talking pathways culminates in a net inhibitory effect on cell growth, one of the crucial determinants of the fate of a tumor. It is likely that such mechanistic pleiotropism by NO-ASA is central to its efficacy against cancer.](Image 249x665 to 304x710)
component of this array of signaling molecules [7, 16–19]. Below, after an overview of the role of PPARδ in cancer, we discuss the relationship between NO-ASA and PPARδ.

3. PPARδ AND CANCER

PPARs, having their first member cloned in 1990 [20], are ligand-activated transcription factors belonging to the superfamily of nuclear receptors. They facilitate the response of cells to extracellular stimuli by transcriptionally regulating gene expression [21, 22]. Three distinct PPAR subclases have been identified: PPARα, PPARδ (also referred to as PPARβ/δ), and PPARγ. These isoforms are encoded by separate genes and differ in their tissue distribution and function. PPARδ is the more ubiquitously expressed isoform. Each of the PPAR isoforms heterodimerizes with the 9-cis-retinoic receptor, their obligate partner. PPARs regulate diverse physiological processes ranging from lipogenesis to inflammation, and have been implicated in several disorders including the metabolic syndrome, diabetes, and atherosclerosis, as well as cancer. More recently, PPARγ was shown to play a significant role in cell growth, inflammation, apoptosis, and angiogenesis [23–27].

The study of PPARδ lags behind our fairly advanced understanding of PPARα and PPARγ; the development of high-affinity PPARδ agonists has recently expedited progress [28, 29]. PG1, and cPGI are naturally occurring PPARδ agonists [30]. PPARδ is involved in a wide range of phenomena affecting several functions, and some of them are critical to the life of an organism. PPARδ stimulates fatty acid oxidation in heart and skeletal muscle [31, 32], and plays a role in cell differentiation [33–35], placental development [36], cancer, wound repair [37], and atherosclerosis [38–41]. PPARδ-null mouse models revealed that PPARδ deficiency is associated with multiple developmental and metabolic abnormalities, including frequent embryonic lethality [36].

4. THE PROS AND CONS FOR A ROLE OF PPARδ IN CANCER

There have been both significant work on and significant excitement about a potential role of PPARδ in cancer. As with any evolving field, some controversy is almost inevitable. This controversy arises mainly from the varying results from animal studies (summarized in [42]). Available data can be divided into two: those which support the notion that PPARδ plays a crucial role in carcinogenesis, and those which indicate that PPARδ is devoid of any such role. Below, we present the main points supporting each one of these antithetic conclusions (Table 1).

4.1. Pros

PPARδ was ascribed an oncogenic function after being identified as a direct transcriptional target of β-catenin, and as a repression target of the NSAID sulindac, a potent suppressor of colorectal tumors [44]. A close association between PPARδ and colon carcinogenesis was suggested by immunohistochemical analyses showing that the expression of PPARδ increases progressively as the colonic epithelium advances from normal to malignant [45].

A series of observations in Min mice support a procarcinogenic role of PPARδ. When Min mice were treated with azoxymethane, PPARδ levels were increased in flat dysplastic aberrant crypt foci [65], although the same authors indicate that PPARδ expression in adenomas from Min mice does not differ compared to normal epithelium [65]. Deletion of PPARδ decreased intestinal adenoma growth and inhibited the tumor-promoting effects of a PPARδ agonist [51]. Interestingly, the same group also showed that prostaglandin E2 (PGE2), the predominant prostanooid found in most colorectal cancers, indirectly transactivates PPARδ promoting cell survival and intestinal adenoma formation [53]. PGE2 treatment did not increase intestinal adenoma burden in Min mice lacking PPARδ, concluding that PPARδ is a focal point of cross-talk between the prostaglandin and Wnt signaling pathways, which results in a shift from cell death to cell survival, leading to increased tumor growth [53]. Treatment of Min mice with a synthetic agonist of PPARδ increased significantly the number and size of intestinal polyps. The most prominent effect was on polyp size; the PPARδ activator increased the number of polyps by >2 mm five-fold [47]. The same group also showed that compared with control ApcMin/+ mice (Ppard+/ApcMin/+), small intestinal polyps in PPARδ-deficient ApcMin/+ mice (Ppard−/−/ApcMin/+), were reduced three-fold; the number of large polyps (>1 mm) was reduced about ten-fold. Heterozygous deletion of PPARδ (Ppard+/−/ApcMin+) did not significantly reduce the total number of small and large intestinal polyps in male mice, but this disruption significantly diminished the number of small intestinal polyps that were >1 mm [51].

In cultured colon cancer cells, PPARδ inhibited differentiation, conferred apoptotic resistance, and promoted cell migration [43], whereas prostacyclin, a metabolic product of COX-2 which modulates intestinal tumorigenesis [66], increased PPARδ activity [43]. PPARδ expression was elevated in colon cancer cells and was repressed by apc via the β-catenin/TCF-4 response elements in its promoter [44]. Genetic disruption of Ppard decreased the tumorigenicity of human colon cancer cells [46]. HCT116 Ppard−/− cells, inoculated as xenografts onto nude mice, exhibited decreased ability to form tumors compared to Ppard+/− and wild-type controls [46]. Dietary fish oil/pectin protected rats against radiation-enhanced colon cancer by upregulating apoptosis in colonic mucosa, in part, by suppressing PPARδ [48].

Data from noncolonic cell lines and tissues also support a role for PPARδ in cancer. Activation of PPARδ results in increased growth in sex hormone-responsive breast (T47D, MCF7) and prostate (LNCaP, PNT1A) cell lines [52]. Epithelial ovarian cancer cells express high levels of PPARδ, and inhibition of PPARδ reduced tumor growth [50]. In epithelial ovarian cancer cells, aspirin suppressed PPARδ function and cell growth by inhibiting ERK1/2 [50]. Activation of PPARδ by its pharmacologic ligand GW501516 enhanced the growth of human hepatoma cell lines, whereas PPARδ knockdown by siRNA prevented cell
Table 1: The pros and cons for a role of PPARδ in cancer.

| Evidence                                                                 | Reference |
|-------------------------------------------------------------------------|-----------|
| **Pros**                                                                |           |
| PPARδ expression is enhanced in colon cancer cells                      | [43]      |
| PPARδ expression is repressed by the APC gene                            | [44]      |
| PPARδ expression increases as tumor progresses                           | [45]      |
| PPARδ genetic disruption decreases tumorigenicity of colorectal cancer cells | [46]      |
| PPARδ activation accelerates intestinal adenoma growth in *Min* mice    | [47]      |
| *Ppard*−/− HCT116 cells exhibit decreased ability to form xenograft tumors | [46]      |
| Dietary fish oil/pectin protects against radiation-enhanced colon cancer by upregulating apoptosis, in part, through PPARδ suppression | [48]      |
| PPARδ expression levels are correlated with advanced pathological tumor stage in tumor patients | [49]      |
| PPARδ-targeted removal of a hub node of the angiogenic network markedly impairs angiogenesis and tumor growth in mice | [49]      |
| Inhibition of PPARδ function reduces growth of epithelial ovarian cancer | [50]      |
| Activation of PPARδ upregulates VEGF in colon cancer cells               | [51]      |
| PPARδ activation stimulates the proliferation of human breast and prostate cancer cell lines | [52]      |
| PGE2 indirectly transactivates PPARδ promoting cell survival and intestinal adenoma formation | [53]      |
| **Cons**                                                                |           |
| PPARδ-null *Min* mice exhibit increased predisposition to intestinal tumorigenesis | [54]      |
| PPARδ-deficient mice show higher polyp formation                          | [55]      |
| PPARδ agonists do not increase cell growth in human cancer cell lines    | [56]      |
| PPARδ is dispensable for polyp formation in the intestine and colon of *Min* mice | [36]      |
| RNA interference against *Ppard* promotes proliferation of HCT116 cells | [57]      |
| Lung tumorigenesis is attenuated in mice with disrupted *Ppard*            | [58]      |
| PPARδ does not modify impaired mismatch repair-induced neoplasia          | [59]      |
| PPARδ promotes differentiation, inhibiting cell proliferation in keratinocytes | [60]      |
| PPARδ ligands inhibit TNFα-induced expression of the vascular cell adhesion molecule-1 and E-selectin in HUVEC, preventing inflammation | [61]      |
| Inhibition of colon carcinogenesis by a PPARδ agonist in an azoxymethane mouse model | [62]      |
| PPARδ activators inhibit TNFα-induced endothelial inflammation, in part by interfering with the NF-κB signaling pathway | [63]      |
| PPARδ activation by a PPARδ agonist produces no change in colon cancer cell growth | [52]      |
| PPARδ activation by GW0742 inhibits colon polyp multiplicity in *Ppard*+/− mice, but not in *Ppard*−/− mice | [64]      |

growth [67]. In murine knockout experiments, targeted removal of a hub node (PPARδ) of the angiogenic network markedly impaired angiogenesis and tumor growth [49]. In human cholangiocarcinoma, a positive feedback loop between PPARδ and PGE2 was recognized; this interaction plays an important role in cell growth [68]. In patients with pancreatic cancer, PPARδ levels were correlated with advanced pathological tumor stage, increasing the risk of tumor recurrence and distant metastases [49].

4.2. Cons

The strongest evidence that PPARδ plays no appreciable role in carcinogenesis comes from a series of animal studies, cell culture data, and from studies evaluating the role of PPARδ in inflammation, the latter being considered as a contributor to carcinogenesis.

Barak et al. evaluated the hypothesis that if PPARδ is a critical transducer of the tumorigenic signal, then its loss should substantially reduce, if not eliminate, intestinal polyps in *Min* mice [36]. *Min* mice that were *Ppard*−/− harbored intestinal and colonic polyps. Histologically, all of the 12 intestinal polyps from *Ppard*+/+ mice and the 9 from *Ppard*−/− mice were low-grade tubular adenomas. The number of intestinal polyps was not significantly different between *Ppard*+/+, *Ppard*+/−, and *Ppard*−/− *Min* mice. Loss of PPARδ did not significantly change the median size of intestinal polyps, although polyps > 1 mm were decreased upon PPARδ dosage reduction, which was further
pronounced for polyps > 2 mm. The number of polyps < 1 mm was essentially identical in all PPARδ genotype groups. Their conclusion was that PPARδ is qualitatively dispensable for the tumorigenic process, although they could not rule out the possibility that it influences the pace of polyp growth. In agreement with these findings, Marin et al. showed that PPARδ activation by GW0742 inhibits colon polyp multiplicity in Ppard+/+ but not in Ppard−/− mice, suggesting that ligand activation of PPARδ attenuates azoxymethane-induced colon carcinogenesis [64].

The most striking results provided by a study demonstrating that in Min mice differing in their Ppard genotype (Ppard−/−, which did not express PPARδ protein; Ppard+/−; and Ppard+/+), the incidence of polyp formation was not significantly different between groups [54]. In fact, Ppard−/− Min mice had about 3–6 times as many colon polyps as those of Ppard+/− or Ppard+/+ mice. No significant differences in polyp size were found between any of the genotypes. Congruent results were obtained when they examined colon carcinogenesis with a more colon-specific, azoxymethane-induced model. The data from these two different colorectal cancer models suggest that PPARδ attenuates colon carcinogenesis.

Finally, Reed et al. reported that PPARδ-null Min mice exhibited increased predisposition to intestinal tumorigenesis [55]. Another report from the same group, evaluating the incidence and severity of intestinal neoplasia in mice deficient in both PPARδ and the mismatch repair gene Mlh1, showed that deficiency of PPARδ in mice with compromised mismatch DNA repair failed to affect intestinal neoplasia [59], with the implication being that PPARδ is not required for intestinal adenoma formation.

Similar results have been obtained for noncolonic tumors. For example, mice lacking one or both alleles of Ppard had enhanced growth of lung tumors [58]. In another example, the onset of tumor formation, tumor size, and tumor multiplicity of the skin was significantly enhanced in PPARδ-null mice compared with wild-type mice [69].

There are also data from cell culture models contradicting the notion that PPARδ plays a role in carcinogenesis. For example, in several human cancer cell lines, two PPARδ ligands failed to increase cell growth, Akt phosphorylation, or the expression of VEGF or COX-2 [56]. PPARδ activation by a PPARδ agonist does not induce cell growth in HT29, SW480, and HCA-7 colon cancer cells [64]. Furthermore, Raf oncogenes can contribute to tumorigenesis by augmenting the secretion of tumor growth promoting prostaglandins, such as PGI2. However, using several cell lines, Fauti et al. showed that the increase in PGI2 synthesis did not induce the transcriptional activity of PPARδ, suggesting that the oncogenic effect of PGE2 does not involve PPARδ [70]. Another PPARδ function is the modulation of cell cycle. Knockdown of the PPARδ gene by siRNA promoted proliferation of HCT116 cells, suggesting that PPARδ may, in fact, inhibit their proliferation by arresting them in the G1 phase of the cell cycle [57].

The chemopreventive action of PPARδ is also suggested by studies showing that in many cell types PPARδ promotes differentiation and inhibits proliferation [33, 60, 69, 71]. For example, Hollingshead et al. examined in azoxymethane-treated PPARδ-null mice whether PPARδ activation and COX2 inhibition attenuate colon cancer independently. Inhibition of COX2 by nimesulide attenuated colon cancer, and activation of PPARδ by GW0742 had inhibitory effects. The effects of these compounds occurred through independent mechanisms as increased levels of differentiation markers resulting from ligand activation of PPARδ were not found with COX-2 inhibition, and reduced PGE2 levels resulting from COX-2 inhibition were not observed in response to ligand activation of PPARδ [62]. In another study by the same group, wild-type (Ppard+/+) and Ppard−/− mice were treated with azoxymethane, together with GW0742, a specific PPARδ ligand, to test if Ppard−/− mice exhibit increased colon polyp multiplicity [64]. Ligand activation of PPARδ in Ppard+/+ mice increased the expression of mRNA encoding the adipocyte differentiation-related protein, fatty acid-binding protein, and cathepsin E, all being indicative of colonocyte differentiation [64]. Thus, the induction of differentiation and the inhibition of proliferation in response to PPARδ activation support the hypothesis that PPARδ attenuates colon carcinogenesis [62].

Another contrarian point of view concerns the role of PPARδ in inflammation, with studies suggesting that activation of PPARδ has anti-inflammatory effects. In hepatocytes, the PPARδ agonist suppressed IL-6-mediated acute phase reaction, prompting the speculation that PPARδ agonists may be used to suppress systemic inflammatory reactions in which IL-6 plays a central role [72]. Two synthetic PPARδ ligands inhibited TNFα-induced expression of the vascular cell adhesion molecule-1 and E-selectin in human umbilical vein endothelial cells, suggesting that PPARδ activation has a potent anti-inflammatory effect [61].

Relevant to cancer is the presumed role of PPARδ in inflammation and NF-κB regulation [63, 73, 74]. Such a role is exemplified by studies on the skin, where activation of PPARδ by IFN-γ and TNFα accelerated keratinocyte differentiation [75]. Studies with PPARδ agonists have shown anti-inflammatory properties of PPARδ attributed to inhibition of NF-κB DNA-binding activity [74, 76]. Inflammation induced by TPA (O-tetradecanoylphorbol-13-acetate) in the skin was lower in wild-type mice fed sulindac than in similarly treated PPARδ-null mice [77]. In human endothelial cells, PPARδ activators inhibited TNFα-induced endothelial inflammation (VCAM-1 expression, monocyte adhesion, and MCP-1 secretion), in part by interfering with the NF-κB signaling pathway [63]. Lipopolysaccharide-induced TNFα production in cultured cardiomyocytes through NF-κB activation was inhibited by overexpression of PPARδ or the PPARδ synthetic ligand GW0742 [73].

The foregoing arguments and counterarguments make it clear that this controversy remains unresolved. This is the reason why we attempted to obtain an insight into the role of PPARδ in carcinogenesis by exploiting the unique opportunity offered by studying the effect of NO-ASA on PPARδ. Our work is presented in the following section.
5. NO-NSAIDs AND PPARδ

Our limited understanding of the mechanism by which NO-ASA exerts its colon chemopreventive effect combined with the possibility that PPARδ plays a role in colon carcinogenesis prompted us to assess the expression of PPARδ during intestinal carcinogenesis, and also whether NO-ASA modulates it [7].

We studied Min mice and their congenic (wild-type) mice, C57BL/6J+/–. Three groups of each type of mice were treated for 21 days with vehicle or m-NO-ASA or p-NO-ASA, each at 100 mg/kg/day. As expected from their relative in vitro potency, after 21 days m-NO-ASA suppressed the number of intestinal tumors in Min mice (wt mice had no tumors) by 38%, and p-NO-ASA by 59%.

Most of the PPARδ positive cells (staining being always nuclear) were in the intestinal villi, with only few in the crypts. PPARδ was minimally expressed among the three groups of wild-type mice. In contrast, the expression of PPARδ in Min mice, similar in tumors and histologically normal mucosa, was more than ten-fold increased compared to wild-type mice. The two NO-ASA positional isomers inhibited the expression of PPARδ in both normal and neoplastic cells of Min mice. m-NO-ASA suppressed PPARδ expression in histologically normal mucosa by 23% and in neoplastic tissue by 41%; p-NO-ASA suppressed PPARδ expression in histologically normal mucosa by 27% and by 55% in neoplastic tissue. The reduction in the number of tumors by each NO-ASA isomer and the respective suppression of PPARδ expression in neoplastic cells are strikingly similar; the meta isomer reduced tumor incidence by 38% and PPARδ expression by 42%, whereas the corresponding reduction for the para isomer was 59% and 55%. Of note, the expression of PPARα and PPARγ was sparse, and treatment with NO-ASA had no appreciable effect on either of them.

The changes in PPARδ expression induced by NO-ASA seemed to have a significant impact on the cell kinetics of the intestinal mucosa, rendering such an effect mechanistically important. The induction of apoptosis by NO-ASA, more prominent in neoplastic epithelial cells, followed closely the pattern of PPARδ reduction. Thus, in the neoplastic tissues, m-NO-ASA increased apoptosis by 22% and p-NO-ASA by 70%. The percentage of changes in PPARδ expression and apoptosis is significantly correlated (P < .03), suggesting a potential etiological association between the two events.

We have previously reported that NO-ASA induces two types of cell death, classical apoptosis as well as atypical cell death, which based on a variety of criteria appears to be a variant of necrosis [4]. Documentation of atypical cell death in vivo had been elusive. This study, however, provided a glimpse into this phenomenon in vivo. As shown in Figure 2, we were able to record the evolution of necrotic areas in NO-ASA-treated intestinal tumors. Initially, TUNEL positive cells coalesce and, as the necrotic area develops, they populate its margins (being extremely rare in the surrounding tissue). As the necrotic area increases in size, the TUNEL positive cells persist at the margins. We have identified multiple TUNEL positive spots within the necrotic areas, suggesting their cellular origin. We believe that these TUNEL positive cells are necrotic cells [78]. The relationship of PPARδ and cell death induced by NO-ASA was ascertained by studying successive sections of intestinal tumors from both treated and untreated animals (Figure 2). Untreated tumors show strong PPARδ expression and few apoptotic cells. After treatment with meta or para NO-ASA, tumors show decreased PPARδ expression and increased apoptosis. If the apoptosis index of tumors from NO-ASA-treated mice is plotted against the expression of PPARδ, the association between the two is statistically significant; Figure 2 makes this correlation obvious. It should, however, be pointed out that these data have two methodological limitations. First, the specificity of the antibody is not considered by experts in the field ideal for immunohistochemistry, as nonspecific binding is possible. Second, no corroborating methodology was employed such as determination of PPARδ protein levels in these tissues by immunoblotting.

Other NSAIDs such as aspirin (of which NO-ASA is a derivative) have been reported to have PPARδ as one of their molecular targets. In epithelial ovarian cancer cells, aspirin suppressed PPARδ function and cell growth by inhibiting ERK1/2 [50]. Sulindac sulfide and indomethacin inhibit both 14-3-3 proteins and PPARδ levels in HT29 cells, suggesting that this could be the mechanism by which NSAIDs induce apoptosis in colorectal cancer [79]. Furthermore, in SW480 cells, sulindac sulfone significantly decreased PPARδ expression more potently than the sulfide metabolite [80]. A case-control study in a large population showed that a polymorphism in the promoter of PPARδ modified the protective effect of NSAIDs on colorectal adenomas [81]. However, the opposite was observed by another group, which found that regular NSAIDs use reduced the risk of colorectal cancer, but none of the polymorphic genes studied, including PPARδ, modified their protective effect [82].

Several reports present evidence that NSAIDs induce apoptosis independently of PPARδ. For example, sulindac significantly inhibited chemically induced skin carcinogenesis in both wild-type and PPARδ-null mice [83]. In addition, aspirin-induced apoptosis in Jurkat cells was not mediated by PPARδ [84]. Aspirin at a concentration which induces apoptosis did not affect the DNA binding of PPARδ, whereas neither addition of a specific PPARδ ligand nor transient transfection of PPARδ expression vectors protected Jurkat cells from aspirin-induced apoptosis. Finally, as the work of Hollingshead et al. presented above suggested, COX-2 inhibition by the NSAID nimesulide and PPARδ activation during colon carcinogenesis occurred through independent mechanisms [62].

6. CONCLUSIONS AND FUTURE DIRECTIONS

The contrast in data that were reviewed here on the potential role of PPARδ in cancer, with colon cancer being most extensively evaluated, could not be starker. Excellent studies from fine laboratories led “conclusively” to diametrically opposite results. As no grey zone seems to exist, the reader is left in bewilderment.

Our data indicate that, compared to wild-type mice, the nuclear receptor PPARδ is overexpressed in the intestinal
Gerardo G. Mackenzie et al.

**Figure 2:** Effect of NO-ASA on PPARδ and apoptosis in colon tissue of Min mice. Upper panel: the evolution of necrotic areas in intestinal tumors treated with p-NO-ASA; sections are stained by the TUNEL method. (I) Coalescence of TUNEL positive cells (arrow), representing the earliest stage; (II) abundant apoptotic cells at the margins of the developing area with contrast to their rarity in the surrounding area; (III) and (IV) the necrotic area is increasing in size, but TUNEL positive cells persist at its margins; TUNEL positive areas within the necrotic areas (arrows) suggest their cellular origin. Lower panel: the relationship of PPARδ and apoptosis in NO-ASA treated intestinal tumors. Successive sections of intestinal tumors were stained for PPARδ expression and apoptosis. The untreated tumor shows strong PPARδ expression (A) and rare apoptotic cells (B). After treatment with meta or para NO-ASA, tumors show decreased PPARδ expression (C) and (E) and increased apoptosis (D) and (F). Magnification is x400, adapted from Ouyang et al. [7].

mucosa of Min mice, and that two isomers of NO-ASA, which suppress their intestinal neoplasia, inhibit to a commensurate degree the expression of PPARδ as well. This effect is accompanied by the induction of epithelial cell death, which correlates well with the antineoplastic effect of NO-ASA. As discussed earlier, these findings are, however, limited by the fact that PPARδ was detected using an antibody whose specificity may not be perfect and also by the lack of any corroborating methodology (e.g., immunoblot detection of PPARδ levels).

One could, nevertheless, consider that these findings support the notion that PPARδ promotes colon carcinogenesis. The key elements of support come from three findings. First, PPARδ is overexpressed in the intestinal mucosa of the Min mice but not in the wild-type control mice; being the same in histologically normal and neoplastic mucosas further suggests that it has a role in early events of carcinogenesis. There is also specificity in the induction of PPARδ, as neither PPARα nor PPARγ was induced. Second, PPARδ responds to two NO-ASA molecules that are structurally identical except for their positional isomerism, proportionally to their antitumor effect. And, third, changes in tumor response, PPARδ, and cytokinetic parameters (apoptosis and necrosis) are closely correlated and mechanistically congruent.

Clarifying the role of PPARδ in colon carcinogenesis and the response to medications is of substantial interest. The mechanistic significance of this question is apparent. The implications for the rational design of therapeutic and/or preventive approaches are also clear. Finally, the fact that PPARδ agonists may be used for other indications raises the
concern of unintended consequences of such modulation of PPARδ, which may have a direct effect on the patient’s risk of colon and perhaps other cancers.

At this stage, the jury should be considered out on the role of PPARδ in cancer. As with any evolving field, the mundane but accurate conclusion is that more work is needed to clarify such an important question.

ACKNOWLEDGMENT

The present work was supported by Grants NIH 2R01 CA92423 and R01 CA101019.

REFERENCES

[1] M. Bolla, S. Momi, P. Gresele, and P. del Soldato, “Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives,” European Journal of Clinical Pharmacology, vol. 62, supplement 1, pp. 145–154, 2006.

[2] B. Rigas, “The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia,” Current Opinion in Gastroenterology, vol. 23, no. 1, pp. 55–59, 2007.

[3] P. del Soldato, R. Sorrentino, and A. Pinto, “NO-aspirins: a class of new anti-inflammatory and antithrombotic agents,” Trends in Pharmacological Sciences, vol. 20, no. 8, pp. 319–323, 1999.

[4] K. Kashfi, S. Borgo, J. L. Williams, et al., “Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 3, pp. 978–988, 2005.

[5] J. A. Baron, “Epidemiology of non-steroidal anti-inflammatory drugs and cancer,” Progress in Experimental Tumor Research, vol. 37, pp. 1–24, 2003.

[6] J. A. Baron, B. F. Cole, R. S. Sandler, et al., “A randomized trial of aspirin to prevent colorectal adenomas,” New England Journal of Medicine, vol. 348, no. 10, pp. 891–899, 2003.

[7] N. Ouyang, J. L. Williams, and B. Rigas, “NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPARδ) expression in APCMin+ mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis,” Carcinogenesis, vol. 27, no. 2, pp. 232–239, 2006.

[8] B. Rigas and K. Kashfi, “Nitric-oxide-donating NSAIDs as agents for cancer prevention,” Trends in Molecular Medicine, vol. 10, no. 7, pp. 324–330, 2004.

[9] K. Kashfi, Y. Ryann, L. L. Qiao, et al., “Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect,” Journal of Pharmacology and Experimental Therapeutics, vol. 359, no. 3, pp. 1273–1282, 2002.

[10] N. Nath, G. Labaze, B. Rigas, and K. Kashfi, “NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression,” Biochemical and Biophysical Research Communications, vol. 326, no. 1, pp. 93–99, 2004.

[11] J. L. Williams, S. Borghi, I. Hasan, E. Castilho, F. Traganos, and B. Rigas, “Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention,” Cancer Research, vol. 61, no. 8, pp. 3285–3289, 2001.

[12] R. K. Yeh, J. Chen, J. L. Williams, et al., “NO-donating nonsteroidal antiinflammatory drugs (NSAIIDs) inhibit colon cancer cell growth more potently than traditional NSAIIDs: a general pharmacological property?” Biochemical Pharmacology, vol. 67, no. 12, pp. 2197–2205, 2004.

[13] J. L. Williams, K. Kashfi, N. Ouyang, P. del Soldato, L. Kopelovich, and B. Rigas, “NO-donating aspirin inhibits intestinal carcinogenesis in Min(APCMin+) mice,” Biochemical and Biophysical Research Communications, vol. 313, no. 3, pp. 784–788, 2004.

[14] C. Leonetti, M. Scarsella, G. Zupi, et al., “Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts,” Molecular Cancer Therapeutics, vol. 5, no. 4, pp. 919–926, 2006.

[15] N. Ouyang, J. L. Williams, G. J. Tsioulias, et al., “Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model,” Cancer Research, vol. 66, no. 8, pp. 4503–4511, 2006.

[16] T. R. Hundley and B. Rigas, “Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 1, pp. 25–34, 2006.

[17] N. Nath, K. Kashfi, J. Chen, and B. Rigas, “Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 12584–12589, 2003.

[18] J. L. Williams, P. Ji, N. Ouyang, X. Liu, and B. Rigas, “NO-donating aspirin inhibits the activation of NF-κB in human cancer cell lines and Min mice,” Carcinogenesis, vol. 29, no. 2, pp. 390–397, 2008.

[19] J. L. Williams, N. Nath, J. Chen, et al., “Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and β-catenin/T-cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: implications for chemoprevention,” Cancer Research, vol. 63, no. 22, pp. 7613–7618, 2003.

[20] L. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.

[21] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors β/δ: emerging roles for a previously neglected third family member,” Current Opinion in Lipidology, vol. 14, no. 2, pp. 129–135, 2003.
[22] M. Robinson-Rechavi, H. Escriva Garcia, and V. Laudet, “The nuclear receptor superfamily,” *Journal of Cell Science*, vol. 116, part 4, pp. 585–586, 2003.

[23] R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” *Nature Reviews Immunology*, vol. 2, no. 10, pp. 746–759, 2002.

[24] S. Z. Duan, M. G. Usher, and R. M. Mortensen, “Peroxisome proliferator-activated receptor-γ-mediated effects in the vasculature,” *Circulation Research*, vol. 102, no. 3, pp. 283–294, 2008.

[25] C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,” *Expert Opinion on Investigational Drugs*, vol. 16, no. 10, pp. 1561–1572, 2007.

[26] A. Krishnan, S. A. Nair, and M. R. Pillai, “Biology of PPARγ in cancer: a critical review on existing lacunae,” *Current Molecular Medicine*, vol. 7, no. 6, pp. 532–540, 2007.

[27] E. A. Thompson, “PPARγ physiology and pathology in gastrointestinal epithelial cells,” *Molecules and Cells*, vol. 24, no. 2, pp. 167–176, 2007.

[28] J. Kasuga, I. Nakagome, A. Aoyama, et al., “Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists,” *Bioorganic & Medicinal Chemistry*, vol. 15, no. 15, pp. 5177–5190, 2007.

[29] H. Miyachi, “Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) δ-selective ligands,” *Current Medicinal Chemistry*, vol. 14, no. 22, pp. 2335–2343, 2007.

[30] B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 9, pp. 4312–4317, 1997.

[31] A. Frederich and P. A. Grimaldi, “Roles of peroxisome proliferator-activated receptor δ in skeletal muscle function and adaptation,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 7, no. 4, pp. 377–381, 2004.

[32] S. Luquet, J. Lopez-Soriano, D. Holst, et al., “Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catalysis. A new target for the treatment of metabolic syndrome,” *Biochimie*, vol. 86, no. 11, pp. 833–837, 2004.

[33] A. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation,” *Cellular Signalling*, vol. 18, no. 1, pp. 9–20, 2006.

[34] I. Saluja, J. G. Granneman, and R. P. Skoff, “PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture,” *Glia*, vol. 33, no. 3, pp. 191–204, 2001.

[35] M. Schmutz, Y. J. Jiang, S. Dubrac, P. M. Elias, and K. R. Feingold, “Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology,” *Journal of Lipid Research*, vol. 49, no. 3, pp. 499–509, 2008.

[36] Y. Barak, D. Xiao, W. He, et al., “Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 1, pp. 303–308, 2002.

[37] N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes,” *Journal of Steroid Biochemistry and Molecular Biology*, vol. 93, no. 2–5, pp. 99–105, 2005.

[38] G. D. Barish, A. R. Atkins, M. Downes, et al., “PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 11, pp. 4271–4276, 2008.

[39] M. A. Bouhlel, B. Staels, and G. Chinetti-Gbaguidi, “Peroxisome proliferator-activated receptors—from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease,” *Journal of Internal Medicine*, vol. 263, no. 1, pp. 28–42, 2008.

[40] B. Pourcet, J.-C. Fruchart, B. Staels, and C. Glineur, “Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis,” *Expert Opinion on Emerging Drugs*, vol. 11, no. 3, pp. 379–401, 2006.

[41] Y. Takata, J. Liu, F. Yin, et al., “PPARδ-mediated antiinflammatory mechanisms inhibit angiogenesis II-accelerated atherosclerosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 11, pp. 4277–4282, 2008.

[42] Z. Nahle, “PPAR trilogy from metabolism to cancer,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 7, no. 4, pp. 397–402, 2004.

[43] R. A. Gupta, J. Tan, W. F. Krause, et al., “Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 24, pp. 13275–13280, 2000.

[44] T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” *Cell*, vol. 99, no. 3, pp. 335–345, 1999.

[45] O. Takayama, H. Yamamoto, B. Damdinsuren, et al., “Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology,” *British Journal of Cancer*, vol. 95, no. 7, pp. 889–895, 2006.

[46] B. H. Park, B. Vogelstein, and K. W. Kinzler, “Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 5, pp. 2598–2603, 2001.

[47] R. A. Gupta, D. Wang, S. Katkuri, et al., “Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth,” *Nature Medicine*, vol. 10, no. 3, pp. 245–247, 2004.

[48] J. Vanamala, A. Glagolenko, P. Yang, et al., “Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARδ/PGE2 and elevation of PGE2,” *Carcinogenesis*, vol. 29, no. 4, pp. 790–796, 2008.

[49] A. Abdollahi, C. Schwager, J. Klee, et al., “Transcriptional network governing the angiogenic switch in human pancreatic cancer,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 31, pp. 12890–12895, 2007.

[50] T. Daikoku, S. Tranguch, A. Chakrabarty, et al., “Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-δ,” *Cytokine*, vol. 51, no. 2, pp. 140–145, 2010.

[51] T. D. Saltzman, B. Staels, and T. Wisse, “PPARδ and PPARγ signaling in metabolic diseases: potential therapeutic targets,” *Expert Opinion on Investigational Drugs*, vol. 19, no. 9, pp. 1419–1429, 2010.
[52] R. L. Stephen, M. C. U. Gustafsson, M. Jarvis, et al., “Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004.

[53] D. Wang, H. Wang, Q. Shi, et al., “Prolaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ,” Cancer Cell, vol. 6, no. 3, pp. 285–295, 2004.

[54] F. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gonzalez, and J. M. Peters, “Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis,” Nature Medicine, vol. 10, no. 5, pp. 481–483, 2004.

[55] K. R. Reed, O. I. Sansom, A. J. Hayes, et al., “PPARα status and Apc-mediated tumourigenesis in the mouse intestine,” Oncogene, vol. 23, no. 55, pp. 8992–8996, 2004.

[56] H. E. Hollingshead, R. L. Killins, M. G. Borland, et al., “Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines,” Carcinogenesis, vol. 28, no. 12, pp. 2641–2649, 2007.

[57] L. Yang, Z.-G. Zhou, X.-L. Zheng, et al., “RNA interference against peroxisome proliferator-activated receptor δ gene promotes proliferation of human colorectal cancer cells,” Diseases of the Colon & Rectum, vol. 51, no. 3, pp. 318–328, 2008.

[58] S. Müller-Brüsselbach, S. Ebrahimsade, J. Jakel, et al., “Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene,” International Journal of Oncology, vol. 31, no. 3, pp. 607–611, 2007.

[59] K. R. Reed, O. I. Sansom, A. J. Hayes, A. J. Gescher, J. M. Peters, and A. R. Clarke, “PPARδ status and mismatch repair mediated neoplasia in the mouse intestine,” BMC Cancer, vol. 6, article 113, 2006.

[60] D. J. Kim, M. T. Bility, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters, “PPARδ/β selectively induces differentiation and inhibits cell proliferation,” Cell Death and Differentiation, vol. 13, no. 1, pp. 53–60, 2006.

[61] Y. Fan, Y. Wang, Z. Tang, et al., “Suppression of pro-inflammatory adhesion molecules by PPAR-δ in human vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 315–321, 2008.

[62] H. E. Hollingshead, M. G. Borland, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters, “Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms,” Carcinogenesis, vol. 29, no. 1, pp. 169–176, 2008.

[63] Y. Rival, N. Benetouë, T. Taillandier, et al., “PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells,” European Journal of Pharmacology, vol. 435, no. 2-3, pp. 143–151, 2002.

[64] H. E. Marin, M. A. Peraza, A. N. Billin, et al., “Ligand activation of peroxisome proliferator-activated receptor δ inhibits colon carcinogenesis,” Cancer Research, vol. 66, no. 8, pp. 4394–4401, 2006.

[65] H. K. Knutsen, H. B. Olstøn, J. E. Paulsen, et al., “Increased levels of PPARβ/δ and cyclin D1 in flat dysplastic ACF and adenomas in APCMin/+ mice,” Anticancer Research, vol. 25, no. 6B, pp. 3781–3789, 2005.

[66] M. Oshima, J. E. Dinchuk, S. L. Kargman, et al., “Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2),” Cell, vol. 87, no. 5, pp. 803–809, 1996.

[67] L. Xu, C. Han, K. Lim, and T. Wu, “Cross-talk between peroxisome proliferator-activated receptor δ and cytokolic phospholipase A2/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells,” Cancer Research, vol. 66, no. 24, pp. 11859–11868, 2006.

[68] L. Xu, C. Han, and T. Wu, “A novel positive feedback loop between peroxisome proliferator-activated receptor-δ and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 33982–33996, 2006.

[69] D. J. Kim, T. E. Akiyama, F. S. Harman, et al., “Peroxisome proliferator-activated receptor β(δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis,” Journal of Biological Chemistry, vol. 279, no. 22, pp. 23719–23727, 2004.

[70] T. Fauti, S. Müller-Brüsselbach, M. Kreutzer, et al., “Induction of PPARβ and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARβ,” FEBS Journal, vol. 273, no. 1, pp. 170–179, 2006.

[71] D. J. Kim, I. A. Murray, A. M. Burns, F. J. Gonzalez, G. H. Perdew, and J. M. Peters, “Peroxisome proliferator-activated receptor-β/δ inhibits epidermal cell proliferation by down-regulation of kinase activity,” Journal of Biological Chemistry, vol. 280, no. 10, pp. 9519–9527, 2005.

[72] T. Kino, K. C. Rice, and G. P. Chrousos, “The PPARδ agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition,” European Journal of Clinical Investigation, vol. 37, no. 5, pp. 425–433, 2007.

[73] G. Ding, L. Cheng, Q. Qin, S. Frontin, and Q. Yang, “PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes,” Journal of Molecular and Cellular Cardiology, vol. 40, no. 6, pp. 821–828, 2006.

[74] A. Planavila, J. C. Laguna, and M. Vázquez-Carrera, “Nuclear factor-κB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy,” Journal of Biological Chemistry, vol. 280, no. 17, pp. 17464–17471, 2005.

[75] N. S. Tan, L. Michalik, N. Noy, et al., “Critical roles of PPARβ/δ in keratinocyte response to inflammation,” Genes and Development, vol. 15, no. 24, pp. 3263–3277, 2001.

[76] J. M. Hall and D. P. McDonnell, “The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages,” Molecular Endocrinology, vol. 21, no. 8, pp. 1756–1768, 2007.

[77] J. M. Peters, S. S. T. Lee, W. Li, et al., “Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000.

[78] S. A. Ben-Sasson, Y. Sherman, and Y. Gaviiri, “Identification of dying cells—in situ staining,” Methods in Cell Biology, vol. 46, pp. 29–39, 1995.

[79] J-Y. Liou, D. Ghezani, S. Yeh, and K. K. Wu, “Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε,” Cancer Research, vol. 67, no. 7, pp. 3185–3191, 2007.

[80] W-C. L. Chang, L. C. Everley, G. R. Pfeiffer II, H. S. Cooper, A. Brusevicius, and M. L. Clapper, “Sulindac sulfone is most effective in modulating β-catenin-mediated transcription in cells with mutant APC,” Annals of the New York Academy of Sciences, vol. 1059, no. 1, pp. 41–55, 2005.
[81] C. L. E. Siezen, M. J. Tijhuis, N. R. Kram, et al., “Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor δ,” *Pharmacogenetics & Genomics*, vol. 16, no. 1, pp. 43–50, 2006.

[82] L. E. McGreavey, F. Turner, G. Smith, et al., “No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPARγ act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma,” *Pharmacogenetics & Genomics*, vol. 15, no. 10, pp. 713–721, 2005.

[83] D. J. Kim, K. S. Prabhu, F. J. Gonzalez, and J. M. Peters, “Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ),” *Carcinogenesis*, vol. 27, no. 5, pp. 1105–1112, 2006.

[84] J. M. López, M. A. Fernández, M. Piqué, and J. Gil, “Aspirin-induced apoptosis in Jurkat cells is not mediated by peroxisome proliferator-activated receptor delta,” *Molecular and Cellular Biochemistry*, vol. 266, no. 1-2, pp. 57–63, 2004.